Please login to the form below
Biogen expands digital safety platform Assessa
The MS technolgy pilot, a collaboration with Ixico, will now include pharmacoviglance reporting
Biogen has expanded work on its digital safety platform, which helps monitor MS patients for signs of the rare and potentially fatel brain infection progressive multifocal leukoencephalopathy (PML).
The pilot programme, a collaboration with tech firm Ixico, will now include pharmacoviglance reporting to monitor patients for previously unreported adverse reactions.
The partners - who have been in a collaborative agreement since October 2015 - developed the Assessa system to provide neurologists with second opinion reading services if there is a suspicion of PML.
Giulio Cerroni, chief executive officer of Ixico, said: “We are delighted to announce the expansion of this pilot involving clinical experts in specialist MS centres and Biogen.
“The Assessa PML digital platform is intended to provide technology and speciality services to physcians involved in delivering care to people living with MS.”
Biogen has invested £1.5m in the project, which is currently being piloted in five EU countries.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Future of MHRA uncertain amid Brexit-fuelled shake up
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- David Hunt launches independent agency The Considered
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Accelerating Drug Development Timelines with Big Data Analytics
- A Lucid Group Thirsty Thursday Special: Beautiful Rejects
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US orders 1.4 million more doses of Regeneron antibody cocktail
- Taking centre stage: the role of behaviour change initiatives in the management of long-term conditions
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- Ovid wins Communiqué Small Consultancy of the Year award at Communiqué 2021
- Lucid Group celebrates a double win at Communiqué 2021
- Future of MHRA uncertain amid Brexit-fuelled shake up
PMHub
Aurora Healthcare Communications
We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
